Assembly Biosciences (ASMB) SEC Filings: History & Chart

Assembly Biosciences, Inc.(ASMB)

Biotechnology · South San Francisco, CA

$22.18-0.56 (-2.46%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Assembly Biosciences, Inc.

Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.

South San Francisco, CA

73 employees

www.assemblybio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jason A. Okazaki

View full financials

Form	Filing Date	Accepted	Document
S-8	Aug 20, 2026	Aug 20, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
8-K/A	Aug 14, 2026	Aug 14, 2026	View filing
10-Q	Aug 13, 2026	Aug 13, 2026	View filing
8-K	Aug 13, 2026	Aug 13, 2026	View filing
SC 13G/A	Aug 13, 2026	Aug 13, 2026	View filing
SC 13G/A	Aug 4, 2026	Aug 4, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
8-K	Jun 5, 2026	Jun 5, 2026	View filing
4	May 27, 2026	May 27, 2026	View filing
SC 13D/A	May 27, 2026	May 27, 2026	View filing
8-K	May 26, 2026	May 26, 2026	View filing
424B5	May 26, 2026	May 22, 2026	View filing
424B5	May 22, 2026	May 22, 2026	View filing
8-K	May 22, 2026	May 22, 2026	View filing
SC 13G	May 11, 2026	May 11, 2026	View filing
10-Q	May 7, 2026	May 7, 2026	View filing
8-K	May 7, 2026	May 7, 2026	View filing
DEFA14A	Apr 22, 2026	Apr 22, 2026	View filing

SEC Filings

Recent Filings